Clover Health Investments (CLOV)

Generated: November 7, 2026

Red Dot

Statistics

Metric	Value
Last Close	$4.81
Blended Price Target	4.19
Blended Margin of Safety	-13.0% Overvalued
Rule of 40 (Next)	53.7%
Rule of 40 (Current)	87.8%
FCF-ROIC	33.8%
Sales Growth Next Year	19.8%
Sales Growth Current Year	54.0%
Sales 3-Year Avg	42.3%
Industry	Healthcare Plans

Analysis

Clover Health is becoming a more credible health-insurance operator, but its business quality still depends heavily on execution. The latest reported quarter showed strong growth: third-quarter 2026 revenue rose 53% year over year to $759 million, Medicare Advantage membership increased 45% to 158,907, and adjusted EBITDA reached $16 million.^[1] Those results suggest improving operating leverage and meaningful demand for Clover’s Medicare Advantage offering.

The revenue outlook is more durable than Clover’s earlier history because Medicare Advantage premiums are recurring and membership growth can compound through annual enrollment cycles. However, the company operates in a regulated, competitive market where margins depend on accurate medical-cost forecasting and effective care management. Clover’s technology may provide useful differentiation, but it is not yet a clearly impregnable moat. Leadership appears more credible after improving profitability and growth, though the track record remains relatively short and execution must remain consistent across changing reimbursement conditions.

What the Company Does

Clover Health offers Medicare Advantage insurance to eligible seniors. It receives fixed per-member payments from the government and uses those payments to cover members’ medical care, administration, and other operating costs. Profitability depends primarily on managing medical expenses below premium revenue while maintaining member retention and regulatory compliance.

The company’s core revenue is insurance revenue from its Medicare Advantage membership. Recent disclosures do not provide a separate, sufficiently current revenue mix that would justify precise segment percentages; qualitatively, the business is overwhelmingly centered on Medicare Advantage rather than a diversified set of unrelated products. Clover also uses its software and clinical tools to support care decisions and member management.

Revenue Recurrence & Predictability

Clover’s revenue is primarily contractual and recurring rather than transactional or project-based. Medicare Advantage members generally generate monthly premium revenue while enrolled, creating substantially better visibility than a conventional fee-for-service technology or services company.

Predictability is nevertheless limited by annual enrollment decisions, member turnover, plan changes, risk-adjustment processes, and medical-cost volatility. Premium rates are governed by government policy and regulatory formulas, while actual claims can fluctuate materially. The latest quarter’s membership growth supports recurring-revenue expansion, but no current disclosure establishes a precise percentage of revenue that is guaranteed or highly predictable.^[1]

Revenue Growth Durability

Clover still serves a small portion of the broad U.S. Medicare Advantage opportunity, leaving room for expansion through new members, geographic growth, and stronger plan adoption. Third-quarter membership growth of 45% year over year indicates that the company is currently gaining scale quickly.^[1] Its principal growth levers are plan design, broker and enrollment execution, retention, and the ability to use technology to improve outcomes without weakening benefits.

The durability of above-market growth is likely measured in years rather than decades. Structural support comes from the aging population and continuing Medicare Advantage adoption, but reimbursement pressure, benefit competition, and policy changes are persistent headwinds. Growth will remain durable only if Clover can convert membership expansion into consistently favorable medical-cost performance rather than relying mainly on enrollment momentum.

Economic Moat

Clover’s strongest potential advantage is its accumulated clinical and claims data, combined with software intended to help physicians identify care needs and manage chronic conditions. Greater scale can improve actuarial information, provider relationships, and operating efficiency. Recurring membership also creates a useful feedback loop: more members generate more data, which can improve care-management tools if the company executes well.

The moat is currently modest and still being tested. Large insurers possess greater scale, broader provider networks, stronger distribution, and deeper administrative resources. Clover’s technology is potentially differentiating but can be copied, licensed, or matched by competitors. Switching costs for members are limited because Medicare Advantage beneficiaries can change plans during applicable enrollment periods. The moat may be widening operationally as Clover grows, but it is not yet clearly protected by network effects or durable cost advantages.

Management & Leadership

Clover is led by CEO Andrew Toy, who has held the role since 2022 and brings a technology-oriented background to the insurer. Recent results suggest improved execution under his leadership, including strong membership growth, higher gross profit, and positive adjusted EBITDA in the third quarter of 2026.^[1] The company’s leadership is not founder-led in the conventional sense.

Current disclosures reviewed here do not provide a sufficiently recent insider-ownership figure to state confidently. Clover has emphasized operating discipline and technology-enabled care management, while recent profitability improvement represents a constructive capital-allocation signal because it reduces dependence on external funding. The leadership record remains relatively short, so sustained performance through adverse claims trends will be the more meaningful test.

Key Risks

Medical-cost risk is central. Clover receives largely fixed premiums but bears the cost of members’ care, so unusually high hospital utilization, inaccurate risk adjustment, or weaker-than-expected coding can quickly pressure results. Government reimbursement changes and Medicare Advantage policy reforms could also reduce benefits or increase compliance costs.

Competition is intense from national insurers, regional plans, and technology-enabled healthcare companies. Larger rivals can spend more on benefits, distribution, provider contracting, and marketing. Clover’s software may improve care management, but failure to demonstrate repeatable clinical and economic benefits would weaken its differentiation.

Operational and regulatory risks remain significant as membership expands. Rapid growth can strain claims administration, customer service, provider coordination, and compliance systems. The business also depends heavily on Medicare Advantage rather than a broad portfolio of revenue sources, making it particularly exposed to government policy, enrollment dynamics, and changes in the senior-insurance market.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of November 7, 2026 November 7, 2026